QQQ ETF Falls 0.3%, Underperforms Underlying Index
Dow Jones2026/10/07 20:36This article was automatically generated using Dow Jones technology. Shares of Invesco QQQ Trust Series I shed 0.3% to $757.73 Wednesday on what proved to be an overall poor trading session for the U.S. stock market, with the S&P 500 Index falling 0.2% to 7,801.77. The fund's fall snapped a six-day winning streak. The fund's underlying index, the NASDAQ 100 Index (NASDAQ Calculation), fell 0.2%. The ETF's shares closed 0.7% below the 52-week high of $762.86 seen on October 6, 2026. Trading volume was 24,473,402, compared to the 65-day average trading volume of 35,198,904. As of October 6, the fund's net asset value totaled $759.50 per share. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 07, 2026 16:36 ET (20:36 GMT)
This article was automatically generated using Dow Jones technology.
Shares of Invesco QQQ Trust Series I shed 0.3% to $757.73 Wednesday on what proved to be an overall poor trading session for the U.S. stock market, with the S&P 500 Index falling 0.2% to 7,801.77.
The fund's fall snapped a six-day winning streak. The fund's underlying index, the NASDAQ 100 Index (NASDAQ Calculation), fell 0.2%.
The ETF's shares closed 0.7% below the 52-week high of $762.86 seen on October 6, 2026.
Trading volume was 24,473,402, compared to the 65-day average trading volume of 35,198,904.
As of October 6, the fund's net asset value totaled $759.50 per share.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 07, 2026 16:36 ET (20:36 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks
Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.
Crypto prices
More
